Skip to main content

What is the difference between Nivestym and Neupogen?

Medically reviewed by Last updated on Sep 11, 2023.

Official answer


Nivestym (filgrastim-aafi) is a biosimilar to Neupogen,

A biosimilar is a biological product that is highly similar to a biologic already approved by the FDA (known as the reference product, in this case Neupogen) and has no clinically meaningful differences in terms of safety, purity and potency from the reference product. Biosimilars can provide cost effective treatment options to already approved biologics.

Nivestym cannot be interchanged with Neupogen at the pharmacy level; the physician must specifically order Nivestym.

Nivestym (filgrastim-aafi) is a recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen indicated for the treatment of neutropenia associated with chemotherapy and related conditions.

Nivestym is used for the same indications as Neupogen.

Learn More: What Are Biosimilars? Top Facts You May Not Know

Related medical questions

Drug information

Related support groups